Email this Page

1. LECTURE OVERVIEW
2. TABLE OF CONTENTS
3. FACULTY
4. TECHNICAL HELP

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Developing the Next Generation of Immunotherapeutic Strategies for Solid Tumors symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Sanjiv S. Agarwala, MD
Paid Consultant – Bristol-Myers Squibb Company; Speaker’s Bureau – Novartis Pharmaceuticals Corporation, sanofi-aventis U.S., Wyeth Pharmaceuticals

John Kirkwood, MD
Research Funding – AstraZeneca, Bristol-Myers Squibb Company, KuDOS Pharmaceuticals Limited, Pfizer Inc., Schering-Plough Corporation; Speaker’s Bureau – Schering-Plough Corporation, The Strategic Edge, Inc.

Nevin Murray, MD
Paid Consultant – AstraZeneca, Eli Lilly and Company

Susan Slovin, MD, PhD
Paid Consultant – Synarc Inc.; Speaker’s Bureau – AstraZeneca, Novartis Pharmaceuticals Corporation, sanofi-aventis U.S.

PER Editorial Staff
No relevant relationships to disclose

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.

Commercial Support

Educational grants for this activity were provided by Bristol-Myers Squibb and Provectus Pharmaceuticals, Inc.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

• Microsoft Internet Explorer (Outside Source)
• Mozilla Firefox (Outside Source)

Additional software requirements include:

• Adobe Flash Player (Outside Source)
• Apple iTunes for Podcast (Outside Source)
• Adobe Acrobat Reader (Outside Source)

Macintosh Users
Compatible Web browsers include:

• Mozilla Firefox (Outside Source)
• Apple Safari (Outside Source)

Additional software requirements include:

• Adobe Flash Player (Outside Source)
• Apple iTunes for Podcast (Outside Source)
• Adobe Acrobat Reader (Outside Source)

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

This activity is not sanctioned by, nor a part of, the 45th Annual Meeting of the American Society of Clinical Oncology.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource.

All correspondence should be directed to:
Editor, Developing the Next Generation of Immunotherapeutic Strategies for Solid Tumors
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:

1. Bristol-Myers Squibb
2. Provectus Pharmaceuticals, Inc.